Re (T = 89.24 h, [Formula: see text] 346.7 keV, [Formula: see text] ), an intense beta-emitter shows great potential to be used as an active material in therapeutic radiopharmaceuticals due to its suitable physico-chemical properties. Re can be produced in several ways, however charged-particle induced reactions show to be promising towards no carrier added production. In this work, production cross-sections of Re were evaluated following the light-charged particle induced reactions on tungsten. An effective evaluation technique such as Simultaneous Evaluation on KALMAN code combined with least squares concept was used to obtain the evaluated data together with covariances. Knowledge of the underlying uncertainties in evaluated nuclear data, i.e., covariances are useful to improve the accuracy of nuclear data.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apradiso.2018.01.035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.
Vaccines (Basel)
December 2024
Internal Medicine, Faculty of Medicine and Surgery, Unicamillus, International School of Medicine, 00131 Rome, Italy.
Unlabelled: mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy to adapt should the antigen vary, and able to induce humoral and cellular immunity.
Methods: To date, only two COVID-19 mRNA and one RSV vaccines have been approved. However, several mRNA vaccines are currently under development for the prevention of human viral (influenza, human immunodeficiency virus [HIV], Epstein-Barr virus, cytomegalovirus, Zika, respiratory syncytial virus, metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster virus, and herpes simplex virus 1 and 2), bacterial (tuberculosis), and parasitic (malaria) diseases.
The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial.
Vaccines (Basel)
December 2024
Henan Province Center for Disease Control and Prevention, Zhengzhou 450003, China.
Objectives: This study aimed to evaluate the immunogenicity and safety of a 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/TT) (PCV13i) in infants.
Methods: A total of 1200 infants were randomly assigned to either the experimental PCV13i group or the control PCV13 group in a 1:1 ratio. Each group received a three-dose series of the vaccine at 2, 4, and 6 months of age, followed by a booster dose at 12-15 months.
Oral Vaccine Formulation for Immunocastration Using a Live-Attenuated ΔSPI2 Strain as an Antigenic Vector.
Vaccines (Basel)
December 2024
Laboratorio de Vacunas Veterinarias, Departamento de Ciencias Biológicas Animales, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santa Rosa 11735, La Pintana, Santiago 8820808, Chile.
Immunization against Gonadotropin-Releasing Hormone (GnRH) has been successfully explored and developed for the parenteral inoculation of animals, aimed at controlling fertility, reducing male aggressiveness, and preventing boar taint. Although effective, these vaccines may cause adverse reactions at the injection site, including immunosuppression and inflammation, as well as the involvement of laborious and time-consuming procedures. Oral vaccines represent an advancement in antigen delivery technology in the vaccine industry.
View Article and Find Full Text PDFThe Impact of HIV on B Cell Compartment and Its Implications for COVID-19 Vaccinations in People with HIV.
Vaccines (Basel)
December 2024
Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
HIV causes intense polyclonal activation of B cells, resulting in increased numbers of spontaneously antibody-secreting cells in the circulation and hypergammaglobulinemia. It is accompanied by significant perturbations in various B cell subsets, such as increased frequencies of immature/transitional B cells, activated memory B cells, atypical memory B cells, short-lived plasmablasts and regulatory B cells, as well as by decreased frequencies of resting memory and resting naïve B cells. Furthermore, both memory and antigen-inexperienced naïve B cells show exhausted and immune-senescent phenotypes.
View Article and Find Full Text PDFChallenges and New Directions in Therapeutic Cancer Vaccine Development.
Vaccines (Basel)
November 2024
Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China.
Tumor vaccine is a promising immunotherapy for solid tumors. Therapeutic tumor vaccines aim at inducing tumor regression, establishing durable antitumor memory, and avoiding non-specific or adverse reactions. However, tumor-induced immune suppression and immune resistance pose challenges to achieving this goal.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!